These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 18765504

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding.
    Delaney JA, Opatrny L, Brophy JM, Suissa S.
    CMAJ; 2007 Aug 14; 177(4):347-51. PubMed ID: 17698822
    [Abstract] [Full Text] [Related]

  • 3. Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs.
    Hebert C, Delaney JA, Hemmelgarn B, Lévesque LE, Suissa S.
    Pharmacoepidemiol Drug Saf; 2007 Aug 14; 16(8):845-9. PubMed ID: 17563091
    [Abstract] [Full Text] [Related]

  • 4. Control for seasonal variation and time trend in case-crossover studies of acute effects of environmental exposures.
    Bateson TF, Schwartz J.
    Epidemiology; 1999 Sep 14; 10(5):539-44. PubMed ID: 10468428
    [Abstract] [Full Text] [Related]

  • 5. Exposure-time-varying hazard function ratios in case-control studies of drug effects.
    Guess HA.
    Pharmacoepidemiol Drug Saf; 2006 Feb 14; 15(2):81-92. PubMed ID: 16287211
    [Abstract] [Full Text] [Related]

  • 6. Validating a method that deals with missing drug information in the Saskatchewan Drug Plan database.
    Tamim HM, Tagalakis V.
    Pharmacoepidemiol Drug Saf; 2009 Feb 14; 18(2):140-6. PubMed ID: 19090502
    [Abstract] [Full Text] [Related]

  • 7. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores.
    Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM.
    Pharmacoepidemiol Drug Saf; 2008 Mar 14; 17(3):297-305. PubMed ID: 18215000
    [Abstract] [Full Text] [Related]

  • 8. Application of case-crossover and case-time-control study designs in analyses of time-varying predictors of T-cell homeostasis failure.
    Schneider MF, Gange SJ, Margolick JB, Detels R, Chmiel JS, Rinaldo C, Armenian HK.
    Ann Epidemiol; 2005 Feb 14; 15(2):137-44. PubMed ID: 15652719
    [Abstract] [Full Text] [Related]

  • 9. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B, Beelen R, Hoek G, Schouten L, Bausch-Goldbohm S, Fischer P, Armstrong B, Hughes E, Jerrett M, van den Brandt P.
    Res Rep Health Eff Inst; 2009 Mar 14; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [Abstract] [Full Text] [Related]

  • 10. [Contribution of case-crossover design to the analysis of short-term health effects of air pollution: reanalysis of air pollution and health data].
    Chardon B, Host S, Pedrono G, Gremy I.
    Rev Epidemiol Sante Publique; 2008 Feb 14; 56(1):31-40. PubMed ID: 18262376
    [Abstract] [Full Text] [Related]

  • 11. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research.
    Schneeweiss S, Stürmer T, Maclure M.
    Pharmacoepidemiol Drug Saf; 1997 Oct 14; 6 Suppl 3():S51-9. PubMed ID: 15073755
    [Abstract] [Full Text] [Related]

  • 12. Bidirectional case-crossover designs for exposures with time trends.
    Navidi W.
    Biometrics; 1998 Jun 14; 54(2):596-605. PubMed ID: 9629646
    [Abstract] [Full Text] [Related]

  • 13. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes.
    Wang PS, Schneeweiss S, Glynn RJ, Mogun H, Avorn J.
    Ann Epidemiol; 2004 Apr 14; 14(4):296-303. PubMed ID: 15066610
    [Abstract] [Full Text] [Related]

  • 14. Estimation of time-dependent rate ratios in case-control studies: comparison of two approaches for exposure assessment.
    Lefebvre G, Angers JF, Blais L.
    Pharmacoepidemiol Drug Saf; 2006 May 14; 15(5):304-16. PubMed ID: 16389656
    [Abstract] [Full Text] [Related]

  • 15. Application of lag-time into exposure definitions to control for protopathic bias.
    Tamim H, Monfared AA, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 Mar 14; 16(3):250-8. PubMed ID: 17245804
    [Abstract] [Full Text] [Related]

  • 16. The case-crossover and case-time-control designs in pharmacoepidemiology.
    Donnan PT, Wang J.
    Pharmacoepidemiol Drug Saf; 2001 May 14; 10(3):259-62. PubMed ID: 11501340
    [No Abstract] [Full Text] [Related]

  • 17. A case-crossover analysis of a case-control study of alcohol consumption and coronary events: the effects of exposure definition and the use of control data.
    Marshall RJ, Wouters S, Jackson RT.
    J Epidemiol Biostat; 2000 May 14; 5(6):367-73. PubMed ID: 11234741
    [Abstract] [Full Text] [Related]

  • 18. When should case-only designs be used for safety monitoring of medical products?
    Maclure M, Fireman B, Nelson JC, Hua W, Shoaibi A, Paredes A, Madigan D.
    Pharmacoepidemiol Drug Saf; 2012 Jan 14; 21 Suppl 1():50-61. PubMed ID: 22262593
    [Abstract] [Full Text] [Related]

  • 19. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L.
    Am J Geriatr Pharmacother; 2009 Jun 14; 7(3):159-66. PubMed ID: 19616184
    [Abstract] [Full Text] [Related]

  • 20. Confounding in database pharmacoepidemiology studies.
    Delaney JA, Opatrny L, Brophy JM, Suissa S.
    Epidemiology; 2008 Mar 14; 19(2):360-1. PubMed ID: 18277175
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.